Home TMU Sitemap FAQ Links
正體中文
Home Ongoing Clinical Trials
Ongoing Clinical Trials

Institution
Principal Investigator
Protocol Title
Keyword
TMU-JIRB No. Protocol Title Institution / Principal Investigator dictionary.testing.TypeOfStudy dictionary.testing.PhasesOfClinicalTrialsForDrugs
N202602002 A preliminary and parallel bioequivalence study to compare three different 9 mg semaglutide tablets in healthy subjects under fasted state. Bioavailability / Bioequivalence (BA/BE) NA
N202602003 A multicenter, randomized, double-blind, parallel group, placebo-controlled study of the efficacy and safety of early depemokimab initiation as add-on treatment in COPD patients with Type 2 inflammation. New Drug Phase Ⅲ
N202602004 A multicenter, multinational, randomized, double-blind, placebo-controlled Phase 3, induction study to evaluate the efficacy and safety of duvakitug in participants with moderately to severely active Crohn’s Disease New Drug Phase Ⅲ
N202602005 PVX4 for the treatment of HPV16+ cervical dysplasia New Drug Phase Ⅱ
N202602006 A Phase I/II, Open-label, Multicenter Study of ALE.P03 (Claudin-1 Targeted Antibody-drug Conjugate) as a Monotherapy in Adult Patients with Selected Advanced or Metastatic CLDN1+ Solid Tumors New Drug Phase Ⅰ
N202602020 A Phase III, Randomized, Investigator-Blinded, Active-Controlled Study of Efficacy and Safety of Efepoetin Alfa for Treatment of Anemia in Patients with Chronic Kidney Disease on Dialysis
TMUH / I-Wen Wu
New Drug Phase Ⅲ
N202602038 A First‑in‑Human, Open‑Label, Single‑Ascending Dose (SAD) and Twice‑Dose (TD) Study of an Inhaled Fixed‑Ratio Combination of Hydroxocobalamin (OHCbl) and Deferoxamine Mesylate (DFO) in Healthy Adults New Drug Phase Ⅰ
N202602039 A multicenter, multinational, randomized, double-blind, placebo-controlled Phase 3, maintenance study to evaluate the efficacy and safety of duvakitug in participants with moderately to severely active Crohn’s Disease New Drug Phase Ⅲ
N202602040 A multicenter open-label extension study to evaluate the long-term safety and tolerability of zigakibart in adults with primary IgA nephropathy New Drug Phase Ⅲ
N202602052 A Phase II Study of Aumolertinib Combined with Phased Chemotherapy for Treatment-Naïve EGFR L858R-Mutated Lung Adenocarcinoma (ACCEL trial) New Drug Academic Research
1 2 38 39 40 41 42 43 44 51 52 / 52

TOP